Xtant Medical Holdings (NYSEAM:XTNT) has seen its one-year price target revised to $1.26 per share, marking a 12.12% increase from the previous estimate of $1.12 on April 12, 2026. This new target reflects a potential upside of 143.70% from the company’s latest closing price of $0.52 per share, with analyst projections ranging from a low of $1.01 to a high of $1.58 per share.
Currently, 37 institutional funds report positions in Xtant Medical, a 2.78% increase from the previous quarter. Institutional ownership has grown by 1.50% over the last three months to 81,405,000 shares, with an average portfolio weight of 0.06%, up 3.41%.
Nantahala Capital Management remains the largest shareholder, holding 68,394,000 shares (48.83% ownership), unchanged from the last quarter. Other notable stakeholders include AWM Investment with 6,594,000 shares (4.71% ownership) and Renaissance Technologies, which increased its stake by 22.39% to 920,000 shares (0.66% ownership).
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
